Fairmount Funds Management LLC bought VRDN
May 11, 2026 · Form 4 insider transaction
Fairmount Funds Management LLC bought 1,176,470 shares of Viridian Therapeutics, Inc. at $17.00 per share, a transaction worth $20.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
1,176,470
Price
$17.00
Total value
$20.00M
Role—
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateMay 11, 2026
Filing dateMay 13, 2026
Shares owned after5,090,928
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.